Nguyen
01-10-2023, 03:41 PM
https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.TPS603
TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer.
https://www.onclive.com/view/trastuzumab-deruxtecan-with-or-without-endocrine-therapy-shows-promising-responses-in-operable-hr-her2-low-breast-cancer
Trastuzumab Deruxtecan, With or Without Endocrine Therapy, Shows Promising Responses in Operable HR+, HER2-Low Breast Cancer
"...Additionally, the study demonstrated that trastuzumab deruxtecan yielded dynamic changes in HER2 tissue expression; 48.6% of patients (n = 17) experienced a change in HER2 IHC expression after trastuzumab deruxtecan treatment. Among patients who experienced a change, 88.2% had a decrease in HER2 expression between baseline and surgery—this included a subset of patients with HER2 IHC-0 disease...."
TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer.
https://www.onclive.com/view/trastuzumab-deruxtecan-with-or-without-endocrine-therapy-shows-promising-responses-in-operable-hr-her2-low-breast-cancer
Trastuzumab Deruxtecan, With or Without Endocrine Therapy, Shows Promising Responses in Operable HR+, HER2-Low Breast Cancer
"...Additionally, the study demonstrated that trastuzumab deruxtecan yielded dynamic changes in HER2 tissue expression; 48.6% of patients (n = 17) experienced a change in HER2 IHC expression after trastuzumab deruxtecan treatment. Among patients who experienced a change, 88.2% had a decrease in HER2 expression between baseline and surgery—this included a subset of patients with HER2 IHC-0 disease...."